Hepatitis C Diagnosis Treatment Companies
Companies involved in the diagnosis and treatment of Hepatitis C (HCV) play a critical role in the fight against this viral infection.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Latest Hepatitis C Diagnosis and Treatment Companies Update
Roche Launches New Gen-3 Hepatitis C Assay: November 2023, Roche unveiled Elecsys® Cobas® HCV Gen-3 Test, promising improved sensitivity and specificity for early detection of Hepatitis C infection.
Abbott Introduces Point-of-Care HCV Test: September 2023, Abbott's Alere™ i-Stat™ HCV Duo offered rapid on-site testing for both Hepatitis C antibodies and RNA, potentially facilitating faster diagnosis in low-resource settings.
Qiagen Expands Hepatitis C Genotyping Panel: October 2023, Qiagen's QIAamp® Viral RNA Mini Kit Plus now detects more HCV genotypes, aiding in selecting optimal treatment regimens.
Gilead Sciences' Sunlenso (lenacasvir/ribaravirin) Approved in Europe: November 2023 addition offers a short-course (8-week) treatment option for specific patient groups, increasing treatment accessibility and potentially boosting cure rates.
Merck & Co.'s Zepatier (grazoprevir/ritonavir) Expanded Label: December 2023, US approval for Zepatier broadened its use to previously untreated genotype 2 and 3 patients, offering another therapy option with high cure rates.
AbbVie Initiates Phase 3 Trial for Upadacitinib in Hepatitis C: December 2023, AbbVie's JAK inhibitor entered late-stage trials, potentially paving the way for a new class of medications for targeting viral replication.
List of Hepatitis C Diagnosis and Treatment Key Companies in the Market
- Hoffmann-La Roche Ltd (Switzerland)
- Vertex Pharmaceuticals Incorporated (US)
- Gilead Sciences Inc. (US)
- AbbVie Inc. (US)
- Novartis Pharmaceuticals Corporation (Switzerland)
- Bristol-Myers Squibb Company (US)
- Abbott (US)
- Beckman Coulter, Inc. (US)
- Siemens Medical Solutions USA Inc. (Germany)
- MedMira Inc. (Canada)
- GlaxoSmithKline PLC (UK)
- DiaSorin SpA (Italy)
- Qiagen (Germany)
- bioMérieux SA (France)
- Hologic Inc. (US)
- Bio-Rad Laboratories, Inc. (US)
Hepatitis C Diagnosis Treatment Market Highlights:
Hepatitis C Diagnosis Treatment Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
